Clinical Management of Cutaneous Adverse Events in Patients on Targeted Anticancer Therapies and Immunotherapies: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
October 2018
in “
Clinical & Translational Oncology
”
cutaneous adverse events papulopustular eruptions xerosis pruritus targeted anticancer therapies immunotherapies dermatological toxicities TKIs EGFR inhibitors immune checkpoint inhibitors skin toxicities skin reactions dry skin itching tyrosine kinase inhibitors epidermal growth factor receptor inhibitors
TLDR Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.
The consensus statement from 2018 by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology provided guidelines for managing cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies. It highlighted the common dermatological toxicities such as papulopustular eruptions, xerosis, and pruritus, which can affect patient quality of life and survival due to necessary treatment modifications. The document emphasized early diagnosis and treatment, a multidisciplinary approach, and the importance of preventive measures. It detailed the clinical features, diagnosis, and management of skin toxicities associated with various drugs, including TKIs, EGFR inhibitors, and immune checkpoint inhibitors. The statement also discussed the potential link between the severity of skin reactions and treatment efficacy, and provided guidelines for grading and managing cutaneous toxicity. Financial support from pharmaceutical companies was acknowledged, but with no influence on the content, and ethical standards were followed with patient consent obtained for image publication.
